Darunavir/Cobicistat
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Therapeutic Concepts, Stanford University, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia, Janssen Pharmaceutical K.K.
Conditions
COVIDCoronavirusHIV InfectionsHIV PositiveHIV-1 InfectionHIV/AIDSHealthyHealthy Volunteers
Phase 1
Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients
CompletedNCT02818348
Start: 2016-06-30End: 2016-11-23Updated: 2018-03-12
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
CompletedNCT03864406
Start: 2019-06-04End: 2022-12-10Updated: 2023-12-01
Phase 2
Phase 4
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects
NCT02404233
Start: 2015-03-31End: 2016-12-31Target: 30Updated: 2015-03-31
A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants
CompletedNCT03123848
Start: 2017-04-14End: 2017-05-19Updated: 2025-02-04
Unknown Phase
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
CompletedNCT00042289
Start: 2003-06-09End: 2020-09-30Updated: 2025-12-02
Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar
CompletedNCT04425382
Start: 2020-03-01End: 2020-09-30Updated: 2022-08-16